$309 Million is the total value of Knoll Capital Management, LLC's 22 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | Medivation, Inc. | $265,190,000 | +31.1% | 4,397,838 | 0.0% | 85.95% | +4.7% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $7,666,000 | +65.2% | 2,563,925 | 0.0% | 2.48% | +31.9% | |
| SYN | Synthetic Biologics Inc. | $6,721,000 | -23.7% | 3,734,149 | 0.0% | 2.18% | -39.1% | |
| ADHD | Alcobra Ltd | $5,008,000 | +18.5% | 1,115,315 | 0.0% | 1.62% | -5.4% | |
| AMPE | Sell | Ampio Pharmaceuticals Inc. | $4,177,000 | -45.2% | 3,238,322 | -4.4% | 1.35% | -56.3% |
| VBLT | New | Vascular Biogenics LTD | $3,967,000 | – | 860,605 | +100.0% | 1.29% | – |
| ABEO | Abeona Therapeutics Inc | $3,209,000 | -7.8% | 1,359,767 | 0.0% | 1.04% | -26.4% | |
| CEMP | Cempra Inc | $2,981,000 | -5.9% | 180,800 | 0.0% | 0.97% | -24.9% | |
| Advaxis Inc. | $2,225,000 | -10.4% | 275,000 | 0.0% | 0.72% | -28.5% | ||
| VNRX | Volition RX LTD | $1,454,000 | -11.2% | 461,538 | 0.0% | 0.47% | -29.2% | |
| KERX | Keryx Biopharmaceuticals Inc. | $1,324,000 | +41.8% | 200,000 | 0.0% | 0.43% | +13.2% | |
| NLNK | Newlink Genetics Corp | $1,153,000 | -38.1% | 102,437 | 0.0% | 0.37% | -50.6% | |
| ALDX | Aldeyra Therapeutics Inc | $773,000 | +35.9% | 135,800 | 0.0% | 0.25% | +8.7% | |
| OHRP | OHR Pharmaceutical Inc | $562,000 | -14.6% | 205,000 | 0.0% | 0.18% | -31.8% | |
| Advaxis Inc.w exp 07/15/201 | $502,000 | -25.8% | 112,500 | 0.0% | 0.16% | -40.7% | ||
| ORPN | Bio Blast Pharma Ltd | $402,000 | -35.7% | 250,970 | 0.0% | 0.13% | -48.8% | |
| EVOK | Evoke Pharma Inc | $381,000 | +34.6% | 55,660 | 0.0% | 0.12% | +7.0% | |
| CLBS | Caladrius Biosciences Inc | $328,000 | -21.3% | 555,781 | 0.0% | 0.11% | -37.3% | |
| CSBR | Champions Oncology INC | $239,000 | -41.0% | 111,111 | 0.0% | 0.08% | -53.0% | |
| GLMD | Sell | Galmed Pharmaceuticals Ltd | $224,000 | -30.0% | 49,947 | -23.2% | 0.07% | -43.8% |
| Aptose Biosciences Inc | $29,000 | -14.7% | 11,933 | 0.0% | 0.01% | -35.7% | ||
| ZSAN | Sell | Zosano Pharma Corp | $15,000 | -65.1% | 11,195 | -39.8% | 0.01% | -70.6% |
| Exit | Vascular Biologics LTD | $0 | – | -333,332 | -100.0% | -0.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.